Business Wire

American Bureau of Shipping Issues Full Class for Saildrone Surveyor Deep-water, Ocean-going USV

27.8.2025 14:00:00 EEST | Business Wire | Press release

Share

Saildrone, the global leader in maritime autonomy, today announced that its Surveyor-class of unmanned surface vehicle (USV) has received full classification from the American Bureau of Shipping (ABS). This milestone follows the Voyager, Saildrone’s coastal and near-shore USV, which received ABS class in 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250827715828/en/

The American Bureau of Shipping (ABS) has issued full classification for the Saildrone Surveyor, a 20-meter USV capable of long-endurance missions in the open ocean, collecting deep-ocean bathymetry and performing a wide range of maritime domain awareness tasks—from anti-submarine warfare (ASW) to trans-ocean cable route surveys. This landmark achievement sets a new global benchmark for unmanned systems and highlights Saildrone’s leadership in developing fully classed, open-ocean-capable USVs.

This landmark achievement sets a new global benchmark for unmanned systems and highlights Saildrone’s leadership in developing fully classed, open-ocean-capable USVs.

While other platforms have received certificates or interim approvals under evolving unmanned vessel frameworks, no other USV or UUV has yet received full classification status from any classification society. ABS is the first to grant full class to an unmanned platform, marking a key milestone for the industry.

The classification notation assigned is ✠A1, DV Naval Craft, AUTONOMOUS (NAV, MNV, PRP, AUX, RO3), which follows the “Rules for Building and Classing Light Warships, Patrol, and High-Speed Naval Vessels (2023).”

“The ABS class certification is more than a certificate—it’s a signal to governments and the maritime industry that Saildrone USVs are mature, safe, tested, and ready for scale,” said Richard Jenkins, Saildrone founder and CEO. “It’s been a very large investment and a multi-year process to achieve ABS Class Certification, but we are proud to be the first company in the world to do so and proud that our systems have reached the highest standards as required by the ABS Class certificate.”

ABS class is an internationally recognized standard for safety, design integrity, and operational reliability. The classification process is a rigorous review and validation of a vessel’s design, construction, and autonomous control systems. For unmanned platforms like the Saildrone Surveyor and Saildrone Voyager, this process includes autonomous control systems, cybersecure communications, structural integrity, and fail-safe redundancies, ensuring the vehicle can safely operate without crew, even in complex, unpredictable ocean conditions.

The 20-meter Surveyor is capable of long-endurance missions in the open ocean, collecting deep-ocean bathymetry and performing a wide range of maritime domain awareness tasks—from anti-submarine warfare (ASW) to trans-ocean cable route surveys. The 10-meter Voyager is designed for persistent surveillance in coastal and near-shore environments, complementing the Surveyor’s blue-water capabilities. Both platforms are capable of fully autonomous operations with no humans on board and are remotely monitored 24/7 by Saildrone’s global Mission Management team.

“ABS and Saildrone are pioneering new frontiers, setting the pace for innovation. This step forward is a result of our investments in ABS’s technical capability and helping to ensure our Rules are able to support innovation with an unwavering focus on safety,” said Patrick Ryan, ABS Senior Vice President and Chief Technology Officer.

Saildrone USVs are currently supporting missions around the world, including ocean mapping, border security, persistent ISR, and critical infrastructure security. With both its Surveyor and Voyager platforms fully classed by ABS, Saildrone is uniquely positioned to support the next generation of naval and commercial unmanned operations.

About Saildrone

Saildrone is a defense company delivering maritime intelligence, surveillance, and reconnaissance products to military, homeland security, and commercial customers. Saildrone unmanned surface vehicles (USVs) are extreme-endurance platforms equipped with advanced sensors and proprietary AI to provide persistent insights above and below the sea surface. Insights that support border security, law enforcement, undersea infrastructure protection, hydrography, and naval power applications. With more than 2,000,000 nautical miles sailed and 50,000 days at sea, Saildrone USVs are trusted by governments across the planet and set the standard for cost-efficient maritime intelligence in the world’s harshest environments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250827715828/en/

Contacts

Jenn Virskus
Director Marketing, Saildrone
Office: (510) 956-8361
jenn.virskus@saildrone.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye